<DOC>
	<DOCNO>NCT02999672</DOCNO>
	<brief_summary>This multicenter , non-randomized , Phase II , single agent study ass efficacy , safety trastuzumab emtansine participant HER2-positive ( immunohistochemistry [ IHC ] 3+ great equal [ &gt; /= ] 30 percent [ % ] tumor cell ) locally advanced metastatic UBC metastatic pancreas/cholangio cancer . Participants must receive least one prior ( bladder cancer platinum-based ) treatment inoperable , locally advanced metastatic tumor . Participants receive intravenous ( IV ) infusion ( infusion duration=90 minute [ min ] ) trastuzumab emtansine unacceptable toxicity , withdrawal consent , disease progression ( PD ) , death , whichever occur first .</brief_summary>
	<brief_title>A Study Evaluate Efficacy , Safety Trastuzumab Emtansine Participants With Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Positive Locally Advanced Metastatic Urothelial Bladder Cancer ( UBC ) Pancreas/Cholangio Cancer ( Kameleon Study )</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Histologically centrally confirm HER2positive ( IHC3+ &gt; /=30 % tumor cell ) : locally advance , metastatic ( treatable curative intent ) UBC pancreas/cholangio cancer There must standard treatment option available participant HER2 overexpressing tumor must undergo least one prior platinumbased treatment inoperable , locally advanced metastatic tumor . ( Note : pancreas/cholangio cancer , prior treatment NOT require platinumbased ) Participant 's lesion measurable accord RECIST V1.1 diagnostic compute tomography ( CT ) scan/magnetic resonance imaging ( MRI ) ; Target lesion ( ) previously irradiate At least one formalinfixed paraffinembedded ( FFPE ) biopsy primary tumor and/or metastatic site require Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 01 No significant cardiac history current leave ventricular ejection fraction ( LVEF ) &gt; /=50 percent ( % ) Adequate organ function Life expectancy least 12 week Participants previous exposure HER2targeted therapy set Participants show histologically confirm focal HER2expression , i.e. , less ( &lt; ) 30 % positively stained tumor cell Participants bone metastasis eligible Participants brain metastasis sole site metastatic disease and/or symptomatic require therapy control symptoms Current uncontrolled hypertension ( systolic &gt; 150 millimeter mercury [ mmHg ] and/or diastolic &gt; 100 mmHg ) Current unstable angina pectoris History symptomatic congestive heart failure ( CHF ) New York Heart Association ( NYHA ) criteria ventricular arrhythmia require treatment History myocardial infarction within last 6 month Peripheral neuropathy , Grade &gt; /=3 Current dyspnea rest due complication advance malignancy , diseases require continuous oxygen therapy Current severe , uncontrolled systemic disease History malignancy within last 5 year Concurrent , serious , uncontrolled infection current know infection human immunodeficiency virus ( HIV ) , active hepatitis B and/or hepatitis C Known prior severe hypersensitivity trastuzumab trastuzumab emtansine excipients investigational medicinal product ( IMP ) Clinically significant bleeding within 30 day enrollment Major surgical procedure significant traumatic injury within 28 day prior randomization anticipation need major surgery course study treatment Concurrent participation therapeutic clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>